Table 4. Results and conclusions of the clinical trial of Minocycline and Magnesium .

mRS: modified ranking scale, mBI: Barthel Index, NIHSS: National Institute of Health Stroke Scale, N/A: not applicable or not described, Na: sodium, K: potassium, IV: Intravenous, g: grams, MRI: magnetic resonance imaging; GCS: Glasgow Coma Scale

Author, Year of Publication	Outcomes	Conclusions
Switzer et al. (2011) [10]	NIHSS, MMP-9 levels	MMP-9 levels were lower at 72 hours comparing with a baseline for both tPA, and non tPA treated subjects with statistically significant results. The tPA group had statistically significantly lower levels at one hour and 24 hours.   The NIHSS was lower after seven days in patients taking minocycline.
Amiri-Nikpour et al. (2014) [4]	NIHSS	NIHSS score was significantly lower in the minocycline-treated group compared with controls. Female participants did not have significant clinical improvement measured by NIHSS compared with males.    Patients who received oral minocycline daily for five days had better neurological outcomes on days 30, 60, and 90 compared to controls.
Kohler et al. (2013) [7]	mRS, NIHSS, mortality	Intravenous minocycline was safe but did not reduce death or dependency after 90 days or improve any functional outcome (mRS, NIHSS).
Padma Srivastava et al. (2012)  [10]	NIHSS, mBI, mRS, MRI characteristics, mortality	mRS was significantly lower on day 90, NIHSS was significantly lower on day 30 and 90 in the treatment group; mBI scores were significantly higher in the treatment group.   MRI T2 DWB imaging did not show a significant difference in the lesion volume between both groups. There was no difference in mortality.
Lampl et al. (2007) [11]	NIHSS,  BI,  mRS, mortality	NIHSS and mRS were significantly lower. At the same time, BI scores were significantly higher in the treatment group. This pattern was apparent since day 7 and maintained on day 30. There was no difference in mortality or hemorrhagic transformation between the two groups.
Aslanyan et al. (2007) [5]	BI, mRS, Glasgow Outcome Score (GOS), mortality	Younger patients, patients with higher baseline diastolic blood pressure, higher mean blood pressure, and absence of ischemic heart disease showed statistically significantly improved results. They showcased the beneficial effect of Mg treatment. Mg improved Barthel index<95, modified Rankin scale>1, and global outcome but not Barthel Index <60. There was no difference in mortality between the two groups.
Pan et al. (2017) [6]	NIHSS, mRS, BI	Patients taking dietary K/Mg salt had greater neurological performance in the NIHSS, MRS, and BI scales after six months.
Shkirkova et al. (2017) [12]	mRS, NIHSS, BI, mortality, GCS	The gravity-controlled method help patient to rapidly achieve steady levels of Mg. Nevertheless, there was no relation between Mg levels and clinical outcomes. Patients with the highest quintiles of Mg level did not modify the day 90 functional outcome (mRS 0-1), 90-day efficacy outcomes of Barthel index>90, NIHSS<1. GCS did not differ between the two groups. Mortality did not differ by quintiles.